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The active site of recombinant hexa-histidine-tagged
human monoacylglycerol lipase (hMGL) is character-
ized by mass spectrometry using the inhibitors 5-((bi-
phenyl-4-yl)methyl)-N,N-dimethyl-2H-tetrazole-2-car-
boxamide (AM6701), and N-arachidonylmaleimide
(NAM) as probes. Carbamylation of Ser129 by AM6701
in the putative hMGL catalytic triad demonstrates
this residue’s essential role in catalysis. Partial NAM
alkylation of hMGL cysteine residues 215 and/or 249
was sufficient to achieve 80% enzyme inhibition.
Although Cys215 and/or Cys249 mutations to alanine(s)
did not affect hMGL hydrolytic activity as compared
with nonmutated hMGL, the C215A displayed height-
ened NAM sensitivity, whereas the C249A evidenced
reduced NAM sensitivity. These data conclusively
demonstrate a sulfhydryl-based mechanism for NAM
inhibition of hMGL in which Cys249 is of paramount
importance. Identification of amino acids critical to
the catalytic activity and pharmacological modula-
tion of hMGL informs the design of selective MGL
inhibitors as potential drugs.
INTRODUCTION
Cannabinoid receptors, their endogenous ligands (endocannabi-
noids), and the enzymes responsible for endocannabinoid
synthesis and deactivation comprise a ubiquitous mammalian
signaling system that regulates diverse physiological functions.
The principal endocannabinoids, N-arachidonoylethanolamine
(anandamide, AEA) (Devane et al., 1992) and 2-arachidonoylgly-
cerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995), are
producedondemandascannabinoid-receptor activating ligands
having distinctive pharmacological profiles. Because unregu-
lated endocannabinoid signaling can have adverse conse-
quences, endocannabinoid concentrations are tightly and
redundantly controlled at points of synthesis, transport, and bio-
transformation of the associated signaling lipids (Di Marzo and
Petrosino, 2007). Enzymatic endocanabinoid deactivation is
key to attenuating endocannabinoid signaling. Fatty acid amide854 Chemistry & Biology 15, 854–862, August 25, 2008 ª2008 Elsevhydrolase (FAAH) is an integral membrane amidase primarily re-
sponsible for AEA hydrolysis that may exist in multiple isoforms
(Cravatt et al., 1996;Wei et al., 2006). Although FAAHalsometab-
olizes 2-AG in vitro (Goparaju et al., 1998), soluble monoacylgly-
cerol lipase (MGL) serves as themajor enzyme for 2-AGdeactiva-
tion in cells (Dinh et al., 2004), perhaps along with subsidiary
MGL-like esterases (Muccioli et al., 2007; Blankman et al., 2007).
Agents that modulate endocannabinoid system transmission
are actively being sought as therapeutics to treat important
behavioral, metabolic, and neurological diseases (Vemuri et al.,
2008; Pacher et al., 2006). For therapeutic upregulation of endo-
cananbinoid signaling, pharmacological inhibition of endocan-
nabinoid deactivating enzymes may offer more selectivity and
less risk of unwanted psychotropic side effects as compared
with cannabinoid-receptor agonists (Malan et al., 2003). Specif-
ically, targeted inhibition of 2-AG deactivation is considered an
attractive therapeutic approach against pain, inflammation,
and neurodegenerative and immune disorders (Pacher et al.,
2006; Saario and Laitinen, 2007). Although many available
FAAH inhibitors also act on MGL (Deutsch et al., 1997; Ghafouri
et al., 2004), high-affinity ligands that potently and selectively in-
hibit MGL are currently lacking. The molecular mechanisms of
known MGL inhibitors are speculative, having been inferred
mainly by analogy from MGL modeling studies with or without
virtual screening (Karlsson et al., 1997; Saario et al., 2006). A
putative MGL catalytic triad (Ser122 . Asp239 . His269) has
been predicted from homology with other serine hydrolases
and limited site-directed mutagenesis experiments (Karlsson
et al., 1997). However, direct experimental demonstration of
the involvement of these (or other) amino acid residues in phar-
macological MGL inhibition is lacking.
First described as aputative competitive inhibitor of AEA trans-
port (IC50 = 270 pM in a cellular assay) with analgesic activity in
rodents (Moore et al., 2005), LY2183240 was subsequently
shown to target mouse-brain FAAH (IC50z13 nM) and recombi-
nantMGL (IC50z5.3nM) in a time-dependentmanner (Alexander
and Cravatt, 2006). FAAH inhibition by LY2183240 was postu-
lated to involve carbamylation of active-site Ser241 (Alexander
and Cravatt, 2006). However, the molecular details of MGL inhi-
bition by LY2183240 remain unknown. In addition, Ortar et al.
(2008) have recently demonstrated that LY2183240 consists of
two isomers, as we have confirmed in the course of LY2183240
synthesis and purification for the present work (data not shown).ier Ltd All rights reserved
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incompletely MGL-like enzymatic activity in rat cerebellar mem-
branes (Saario et al., 2005) and rat adipocyte subcellular frac-
tions (Sakurada and Noma, 1981). As with inhibition of MGL by
LY2183240, no experimental evidence is available regarding
the mechanism of MGL inhibition by NAM. The conjugated
double bond of N-substituted maleimides can undergo a facile
Michael addition to nucleophilic groups of amino acids and, par-
ticularly, the thiol group of cysteine (Smyth et al., 1960). Conse-
quently, NAM’s inhibition of MGL in rat cerebellar membranes
was hypothesized from molecular modeling studies to reflect
an interaction between NAM and either Cys242 or Cys208, these
two of the enzyme’s six cysteine residues having been modeled
proximally to the putative substrate-binding site (Saario et al.,
2005). There are four cysteine residues in human MGL, and their
thiol groups are not involved in disulfide bond formation (Zvonok
et al., 2008).
In the present study, we show that the 2,5-LY2183240 isomer
5-((biphenyl-4-yl)methyl)-N,N-dimethyl-2H-tetrazole-2-carboxa-
mide (AM6701) is a more potent inhibitor of recombinant hexa-
histidine-tagged human MGL (hMGL) than the 1,5-isomer 5-((bi-
phenyl-4-yl)methyl)-N,N-dimethyl-1H-tetrazole-1-carboxamide
(AM6702). We have therefore characterized AM6701-inhibited
hMGL through a comprehensive mass spectrometric (MS) anal-
ysis to identify directly the amino acid residue(s) involved. We
have also successfully applied this ligand-assisted protein struc-
ture (LAPS) approach to obtain the first direct structural informa-
tion on hMGL inhibition by NAM, which we have augmented with
site-directed mutagenesis data. The results are of value in iden-
tifying specific amino acid residues critical to MGL catalysis and
pharmacological modulation, informing thereby the rational de-
sign of selective MGL inhibitors with potential therapeutic utility.
RESULTS AND DISCUSSION
hMGL Inhibition by AM6701 and NAM
SDS-PAGE followedbyeitherCoomassie stainingorwesternblot
anti-5-His antibody detection demonstrated that the hMGL over-
expressed in E. coli and isolated by immobilized metal-affinity
chromatography is a singlemonomeric protein with an estimated
molecular mass, z35 kDa, that approximates the calculated
mass of 34,123 kDa (Figures 1A and 1B). The catalytic properties
of purified hMGL are similar to those of the homologous, soluble
crude rMGL using either 2-AG or a novel fluorogenic reporter,
arachidonoyl,7-hydroxy-6-methoxy-4-methylcoumarin ester
(AHMMCE), as substrate (Zvonok et al., 2008). With a sensitive
fluorescence-based assay, the inhibitor profiles of both
LY2183240 isomers and NAM were first characterized using
E.coli lysate (containinghMGL)andsolublecrude rMGLasenzyme
sources. After 3 hr incubation, the LY2183240 isomers AM6701
and AM6702 inhibited hMGL in the nanomolar range with con-
centration dependence, whereas NAMwasmarkedly less potent
(Figure 1C). Only the LY2183240 2,5-regioisomer (AM6701) in-
hibited both hMGL and soluble crude rMGL with low nM IC50s,
making AM6701 the more potent LY2183240 isomer as well as
the most potent MGL inhibitor profiled (Figure 1D). The high po-
tency of AM6701 as MGL inhibitor relative to both AM6702 and
NAM is supported by published studies using 2-AG as substrate,Chemistry & Biology 15, 8albeit with varying sources of crude MGL(-like) activity (Ortar
et al., 2008; Saario et al., 2005; Figure 1D).
We next defined conditions that would elicit maximal hMGL in-
hibition by either AM6701 or NAM so as to generate, efficiently,
enzyme preparations useful for identifying the amino acid resi-
due(s) critical to each inhibitor’s action by MALDI-TOF MS. At
a fixed substrate concentration of 50 mM AHMMCE, inhibition
of purified hMGL was dependent upon the inhibitor:hMGL molar
ratio (Table 1). Even at an equimolar ratio with hMGL, AM6701
markedly inhibited (by 72%) the enzyme. Maximal inhibition
(90%) of hMGL by AM6701 was attained at an 8.3-fold molar
excess of AM6701 over hMGL. In contrast, an equimolar ratio
of NAM to hMGL resulted in only 50% inhibition. A 3.3:1
NAM:hMGL molar ratio potentiated enzyme inhibition to
80%, whereas up to a 33-fold molar excess of NAM elicited lit-
tle further hMGL inhibition. Identical results were obtained at
a fixed substrate concentration of 100 mM AHMMCE (data not
shown). Consequently, we elected to incubate hMGL for 1 hr
with an 8.3-fold molar excess of AM6701 to characterize by
MALDI-TOF MS all inhibitor-related enzyme modification(s). Be-
cause of the relatively more pronounced concentration-depen-
dence by which NAM inhibited hMGL hydrolysis of fluorogenic
reporter AHMMCE (Table 1), the mechanism of hMGL inhibition
by NAM was studied at the various NAM:hMGL molar ratios
specified in Tables 1 and 2.
MS Analysis of hMGL Inhibition by AM6701
Desalted samples of untreated hMGL and enzyme that had been
inhibited >90%by a 1 hr preincubation with an 8.3-foldmolar ex-
cess of AM6701 were subjected overnight to in-solution trypsin
digestion prior to MALDI-TOF MS analysis. A comparison of the
spectra of the tryptic digest from naive and AM6701-inhibited
hMGL revealed in the latter only one peptide with a 71 Da mass
increase, which was provisionally attributed to the addition of a
single dimethylcarbamyl group to the enzyme (Figure 2A). The
carbamylation product was sensitive to the dithiothreitol-iodoa-
cetamide treatment typically employed to disrupt disulfidebonds
and alkylate free sulfhydryls prior to trypsin digestion. To avoid
complete removal of the carbamyl group from AM6701-inhibited
hMGL, a limited 30 min dithiothreitol-iodoacetamide treatment
(Figure 2A) was conducted prior to MALDI-TOFMS. Under these
mild conditions,30%of the peptide carbamylation observed in
AM6701-inhibited hMGL was retained (Figure 2B).
Figure 3 depicts the MS/MS spectra of the 5247.87 m/z and
5318.79 m/z peptide ions derived from trypsin digests of naive
(Figure 3A) and AM6701-inhibited (Figure 3B) hMGL, respec-
tively. Although the precursor ions are intensive (Figure 2A and
2B),MS/MS spectral optimization is complicated by the highmo-
lecular weights involved, as reflected in the signal-to-noise ratio
of the MS/MS spectra in Figures 3A and 3B. Nonetheless, the
same fragmentation ions corresponding to the y ion for the se-
quence IAGGMSHG (Figure 3A) and the sequence IAGGM
(Figure 3B) are identified. Notably, the masses for the last three
residues (SHG) in the digest of AM6701-inhibited hMGL (Fig-
ure 3B) are 71 m/z greater than in the naive enzyme (Figure 3A).
The high-resolution spectrum of the unmodified precursor ion
at m/z 5247.87 (Figure 3A) corresponds to the tryptic peptide
DYPGLPVFLLGHSMGGAIAILTAAERPGHFAGMVLISPLVLANP
ESATTFKVLAAK (position 117-172), and the second ion at m/z54–862, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 855
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Ligand-Assisted hMGL CharacterizationFigure 1. Purification and Inhibition of hMGL
(A and B) (A) Coomassie stained 10% PAGE-SDS gel and (B) western blot analysis of IMAC-purified, recombinant hexa-histidine-tagged human MGL (hMGL).
(C) Best-fit, one-site plots of the concentration-dependent inhibition by AM6701, AM6702, and NAM of hMGL and designated hMGL cysteine mutants to hydro-
lyze AHMMCE. The inset highlights the biphasic nature of the hMGL C249A mutant by NAM as a two-site plot.
(D) IC50 values for inhibition of soluble crude rMGL, hMGL, and MGL prepared from COS cells and rat cerebellum by AM6701, AM6702, and NAM.5318.79 is the carbamylated (+71 Da) product (Figure 3B). Be-
cause there are three serine residues in the tryptic fragment,
tandemMSwas performed on both the unmodified andmodified
ions to determine the exact serine residue modified by AM6701.
Tandem MS unambiguously identified Ser129 as the hMGL resi-
due carbamylated by AM6701. Mechanistically, the carbamyla-
tion product may arise from an attack by the Ser129 hydroxyl
group on the AM6701 carbonyl moiety, the resultant carbamy-
lated serine accounting for a 71 Da increase in the mass of the
peptide (Figure 3C). Figure 3D (left panel) depicts schematically
the spatial disposition of the amino acid residues Ser129 .
Asp246. His276 in the hMGL catalytic triad (Ser122. Asp239.856 Chemistry & Biology 15, 854–862, August 25, 2008 ª2008 ElsevHis269 in human MGL) in an energetically favorable orientation
with AM6701 before its reaction with enzyme. The carbamylated
Ser129 residue in AM6701-inhibited hMGL is depicted in
Figure 3D (right panel). These data clearly demonstrate the
essential role of Ser129 in the conserved G127XSXG131 motif
(i.e., G120XSXG124 in human MGL) of the catalytic triad for
hMGL esterase activity.
MS and Mutational Analyses of hMGL Inhibition by NAM
The graded concentration dependence by which NAM inhibited
hMGL activity (Figure 1 and Table 1) suggests the presence of
high-affinity inhibitor binding site(s) that are in close proximityier Ltd All rights reserved
Chemistry & Biology
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and that may affect catalysis differentially. This suggestion is di-
rectly supported by MALDI-TOF MS analysis of cysteine-con-
taining peptides in tryptic digests of NAM-inhibited hMGL
(Figure 4A and 4B). At a NAM:hMGL molar ratio of 8.3:1, both
unmodified and NAM-modified peptides at Cys215 or Cys249
were identified (Table 2), the latter evidencing a 369.27 Da
mass increase. Even at the maximal, 33-fold NAM molar excess
Table 1. Concentration Dependence of hMGL Inhibition by
AM6701 and NAM
Inhibitor Inhibitor:hMGL Molar Ratio hMGL Inhibition (%) 10 min
AM6701 1:1 72
3.3:1 85
8.3:1 91
NAM 1:1 51
3.3:1 80
8.3:1 82
33:1 84
Reporter substrate (AHMMCE) concentration was 50 mM.Chemistry & Biology 15, 8employed, comparable incomplete (84%) hMGL inhibition was
observed, and Cys215 or Cys249 was still partially alkylated (Fig-
ure 4B). Based on the intensity of peptide signals in theMS spec-
tra, the relative cysteine alkylation at positions 215 and 249 was
similar at NAM:hMGL molar ratios of 8.3:1 (Cys215, 26% and
Cys249, 74%) and 33:1 (Cys215, 22% and Cys249, 78%) (Table 2).
Thus, a 4-fold increase in NAM concentration affected
neither the relative alkylation of Cys215 andCys249 nor the degree
Table 2. Relative Content of NAM-Modified, Cysteine-Containing
Peptides Identified byMS in Tryptic Digest of NAM-Treated hMGL
hMGL Cysteine
Residues m/z
Relative Percent Alkylation
NAM:hMGL Ratio
8.3:1 33:1
Cys39 3144.62; 3300.72 0 100a
Cys208 2007.05 0 0a
Cys215 2158.28 26b 22b
Cys249 2445.38; 3534.97 74b 78b
aPercent alkylation of Cys39 relative to Cys208.
b Percent alkylation of Cys215 relative to Cys249.Figure 2. Peptide Fingerprinting of AM6701-Inhibited hMGL
The tryptic digest of the AM6701-inhibited hMGL was peptide fingerprinted using MALDI-TOF MS.
(A) The enzyme was subjected to mild reduction-alkylation before trypsin digestion.
(B) The enzyme was digested with trypsin without reduction-alkylation.
High-resolution MS spectra of the precursor ions are shown for the unmodified (m/z 5247.62) and carbamylated (m/z 5318.76) peptide DYPGLPVFLLGHSMG
GAIAILTAAERPGHFAGMVLISPLVLANPESATTFKVLAAK (position 117–172).54–862, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 857
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Ligand-Assisted hMGL CharacterizationFigure 3. MALDI-TOF MS/MS Analysis of hMGL Carbamylation by AM6701
(A and B) TandemMALDI-TOFMS/MS analysis of (A) unmodified and (B) modified peptides identified Ser129 as the hMGL residue carbamylated by AM6701. The
fragmentation ions corresponding to the y-ion sequence IAGGMSHG and IAGGMS(+71)HG are underscored.858 Chemistry & Biology 15, 854–862, August 25, 2008 ª2008 Elsevier Ltd All rights reserved
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Ligand-Assisted hMGL CharacterizationFigure 4. Peptide Fingerprinting of NAM-Inhibited hMGL
(A) The tryptic digest of hMGL inhibited with NAM (at a 33:1 NAM:hMGLmolar ratio) was peptide fingerprinted usingMALDI-TOFMS. High-resolutionMS spectra
of NAM-modified peptide ions are shown in the insets.
(B) As identified by MS, the cysteine-containing peptides without or with NAM attached are presented in the table. The cysteines at positions 39, 215, and 249
modified with NAM are shown in bold (C*) and highlighted in green, blue, and red, respectively.
(C) Schematic illustration of MGL alkylation by NAM.of hMGL inhibition by NAM (Table 1), suggesting that NAM
may modify either Cys249 or Cys215, but not both in the same
hMGL molecule. At the 33:1 NAM:hMGL molar ratio, Cys39
also became alkylated, whereas Cys208 remained unmodifiedChemistry & Biology 15, 8at all NAM:hMGL molar ratios examined (Table 2). MS/MS anal-
ysis of the 1789.04, 2158.28, 2445.37, 3144.55, 3300.75, and
3534.93 m/z peptide ions identified Cys215, Cys249, and Cys39
as the sites of hMGL alkylation by NAM (data not shown).(C) Illustration of the carbamylation reaction between the Ser129 of hMGL and AM6701.
(D) Schematic presentation of the hMGL catalytic triad within which AM6701 is oriented before (left panel) and after (right panel) hMGL inhibition by Ser129 car-
bamylation (Ser*). The carbons of AM6701 and theMGL peptide bonds are depicted in green and gray, respectively. Blue, nitrogen; white, hydrogen; red, oxygen.54–862, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 859
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residue of hMGL and NAM.
Additional evidence regarding the mechanism of MGL inhibi-
tion by NAM was obtained through characterization of cyste-
ine-to-alanine C215A and C249A single and double C215/249A
hMGL mutants. Our data indicate that the catalytic activity of
the single C215A and C249A mutants and the double C215/
249A hMGL mutant did not differ significantly from that of
nonmutated hMGL, as indexed by their ability to hydrolyze
AHMMCE (data not shown). However, we did observe differ-
ences among hMGL and themutant enzymes in their susceptibil-
ity to NAM inhibition (Figure 1C). As evaluated by one-site
regression analysis (Figure 1C), elimination of Cys249 in either
the C249A (IC50 = 6.4 mM) or the C215/249A (IC50 = 8.5 mM)
hMGL mutant reduced the enzyme’s sensitivity to NAM as com-
pared with nonmutated hMGL (IC50 = 2.8 mM). Due to its biphasic
appearance, the NAM concentration-response of the C249A
mutant was further analyzed with a two-site equation. The por-
tion of this concentration-response curve (Figure 1C, inset)
below the inflection region at 50% enzyme activity may reflect
the partial activity of the C249A mutant alkylated by NAM at
Cys215. In marked contrast, the C215A mutant itself was 2-fold
more sensitive to NAM (IC50 = 1.4 mM) than hMGL (IC50 =
2.8 mM). These mutational analyses overall suggest the greater
importance of Cys249 versus Cys215 in hMGL inhibition by NAM.
Our MS and mutation data demonstrate conclusively that
hMGL inhibition by NAM depends upon the differential Michael
addition of an arachidonylmaleimide group to select cysteine res-
idues in the enzyme. Partial alkylation of hMGL at Cys215 and/or
Cys249 with NAM is sufficient to inhibit hMGL by 80%, Cys249
alkylation being favored, whereas Cys39 and Cys208 may not be
critical. Yet large molar NAM excesses do inhibit hMGL com-
pletely (Figure 1C). We hypothesize that, at an 8.3- to 33-fold
molar excess of NAM, either Cys249 or Cys215, but not both, be-
comes alkylated in any given hMGL molecule, Cys249 preferen-
tially (Table 2). As a consequence of this initial alkylation event, ac-
cessibility of the other, unmodified cysteine residue to another
NAM molecule is restricted. Because the C215A hMGL mutant
was more sensitive to NAM than the nonmutated hMGL, and the
C249A mutant was less sensitive to NAM, Cys249 alkylation may
be themore decisive determinant of hMGL inhibition by NAM (rel-
ative to Cys215 alkylation). The partial inhibition of MGL in rat
cerebellar membranes (Saario et al., 2005) and rat adipocyte
fractions (Sakurada and Noma, 1981) by assorted maleimides
suggests that our MS and mutational characterization of hMGL-
NAM interactions might offer some mechanistic context for MGL
inhibition by other N-substituted maleimides across species.
SIGNIFICANCE
Detailed mechanistic understanding of the enzymes that
deactivate endocannabinoids is a prerequisite for the effec-
tive pharmacotherapeutic modulation of the endocannabi-
noid signaling system. Although extant structural informa-
tion on MGL relies heavily on provisional modeling studies,
the present work has used a ligand-assisted, MS-based
approach (termed ligand-assisted protein structure, or
‘‘LAPS’’) augmentedwithmutational analysis to characterize
at themolecular level themechanisms bywhich AM6701 and860 Chemistry & Biology 15, 854–862, August 25, 2008 ª2008 ElsevNAM inhibit this critical endocannabinoid-system enzyme
responsible for deactivating 2-AG, the most abundant brain
endocannabinoid and a full agonist at both cannabinoid re-
ceptors. Potent inhibition of hMGLby the carbamyl tetrazole,
AM6701, was shown to involve a covalent interaction result-
ing in selective enzyme carbamylation at Ser129 (i.e., Ser122 in
human MGL) in the GXSXG motif of the MGL catalytic triad.
Thisfindingconstitutes thefirstdirect confirmationof thees-
sential role of Ser129 for MGL hydrolytic activity. Appreciable
(80%) hMGL inhibition by NAMwas shown to involve cova-
lent Michael addition of an N-arachidonylmaleimide group
to Cys215 and/or Cys249 in hMGL (i.e., Cys208 and Cys242 in
human MGL), somewhat preferentially to the latter cysteine
residue. Cys39 and Cys208 in hMGL (i.e., Cys32 and Cys201 in
human MGL) appear not to play an essential role in partial
hMGL inhibitionbyNAM.Directdemonstrationof the involve-
ment of Ser129 in hMGL inhibition by AM6701, and Cys249 and
Cys215 in hMGL inhibition by NAM, is useful in designing po-
tent, highly selective MGL-targeted inhibitors as drug candi-
dates to treatdisorders (e.g., anxiety, pain, inflammation, and
various neurodegenerative diseases) for which potentiating
endocannabinoid-system activity might be therapeutic.
EXPERIMENTAL PROCEDURES
Materials
Standard laboratory chemicals, culture media, isopropyl-b-D-thio-galactopyr-
anoside, lysozyme, and DNase I were purchased from Sigma Chemical
(St. Louis, MO) and Fisher Chemical (Pittsburgh, PA), unless otherwise speci-
fied. SDS-PAGE supplies and Bio Spin P-6 columns were from Bio-Rad
(Hercules, CA). MS-grade trypsin (Trypsin Gold) was from Promega (Madison,
WI). AM6701, AM6702, and AHMMCEwere synthesized at the Center for Drug
Discovery, Northeastern University, by standard routes that will be detailed
elsewhere. Soluble crude rMGL was prepared essentially as described
(Goparaju et al., 1998).
Mutant hMGL Preparation and Profiling
The cysteine-to-alanine singleC215AandC249A hMGLmutants and the double
C215/249A hMGL mutant were generated using the Stratagene QuickChange
site-directedmutagenesis kit (La Jolla, CA). TheDNAprimary structure of allmu-
tants was confirmed by sequencing. The hMGL mutant enzymes were ex-
pressed in E. coli and assayed for hydrolytic activity with AHMMCE in the ab-
sence or presence of NAM at known concentrations, as described below.
Preparative hMGL Purification by Immobilized
Metal Affinity Chromatography
A single colony of E. coli BL21 (DE3) cells containing the plasmid
pET45His6hMGL was inoculated into 12 ml of Luria broth supplemented with
ampicillin (100 mg/ml) and grown with shaking at 250 rpm overnight at 37C.
The next morning, 10 ml of this culture was inoculated into 1 L of Luria broth-
ampicillin medium, which was incubated with shaking at 37C until reaching
anOD600 of 0.6–0.8. Protein expressionwas inducedbyadding1mM (final con-
centration) isopropyl-b-D-thio-galactopyranoside. After 5 hr induction, E. coli
cells were harvested by centrifugation (5,000 g, 10 min, 4C), washed with
PBS buffer, and stored at 80C. Five grams (wet weight) of cells was resus-
pended in 50 ml lysis buffer (50 mM Tris [pH 8.0] containing 100 mM NaCl
and 0.5% Triton X-100) supplemented with lysozyme (0.2 mg/ml) and DNase
I (25 mg/ml) and disrupted on ice by sonication. The sonicate was centrifuged
(10,000 g, 30 min, 4C), and the supernatant was incubated with 1.0 ml (bed
volume) pre-equilibrated BD Talon metal affinity resin (Takara, Otsu, Shiga,
Japan) at room temperature in a rotator. After 1 hr, the suspension was trans-
ferred to a gravity-flow column and allowed to settle. The resin was washed
with 15 ml lysis buffer, then with 15 ml lysis buffer containing 0.1% Triton
X-100 and 10 mM imidazole to elute unbound material. The recombinantier Ltd All rights reserved
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containing 0.1% Triton X-100 and 200 mM imidazole, and the eluate was
collected in 500 ml fractions that were analyzed by SDS-PAGE.
SDS-PAGE and Western Blot Analysis
Samples were denatured at 70C for 5 min in Laemmli buffer containing 5%
b-mercaptoethanol and resolved on 10% PAGE SDS gels. Gels were either
stained with Commassie blue or transferred to PVDF membranes for immuno-
detection with anti-5His horseradish peroxidase conjugate followingmanufac-
turer’s directions (QIAexpress; QIAGEN, Valencia, CA). Protein bands on the
blots were visualized using the ECL Western Blotting Analysis System (GE
Healthcare, Piscataway, NJ). A FluorChem Imaging System (Alpha Innotech,
San Leandro, CA) was used to photograph developed gels and blots.
Assay of Soluble Crude rMGL and hMGL Hydrolytic Activity
The assay to quantify soluble crude rMGL and hMGL enzymatic activity was
based on the hydrolysis of the novel fluorogenic reporter substrate AHMMCE
and was performed in a 96-well plate (Costar 3650) format using a Synergy HT
Plate Reader (BioTek Instruments, Winooski, VT). To determine overall
concentration-response profiles (Figures 1C and 1D), 8 ml E. coli lysate con-
taining hMGL (175 ng total protein) with or without designated test compound
at specified concentrations in 50 mM Tris-HCl (pH 7.4) containing 8% DMSO
was preincubated for 15 min at room temperature. AHMMCE was next added
to a final concentration 20 mM in a total volume 200 ml. The incubation was
continued for 3 hr, during which fluorescence readings at 360 nm/460 nm
(lexcitation/lemission) were taken every 15 min. Relative fluorescence units
were converted to the amount of 7-hydroxy-6-methoxy-4-methylcoumarin
(HMC) formed from AHMMCE enzymatic hydrolysis based on a standard fluo-
rescence curve of known amounts of HMC. The HMC formed after 2 hr (i.e.,
within the linear assay response) was plotted against test-compound concen-
tration, and a nonlinear regression equation was used to determine IC50 values
(Figure 1D) (Prism software, version 4; GraphPad, San Diego, CA).
Assay of hMGL Inhibition Using AHMMCE
The concentration-dependence of hMGL inhibition (Table 1) was evaluated
after incubation of purified hMGL with test compound for 1 hr at room temper-
ature. The assay was performed in a 96-well format (Costar 3795) in 10 mM
Tris-HCl (pH 8.0) containing 5% DMSO (final volume 20 ml) with hMGL alone
(1 ng) and hMGL (3 ng) that had been incubatedwith test compound at a known
molar ratio to hMGL enzyme, as specified in Table 1. AHMMCE (50 or 100 mM)
was then added as fluorogenic reporter substrate. The plate was exposed to
ultraviolet light (360 nm) for 3 s, and images were recorded at the start of the
assay and every 10 min thereafter for 1 hr using a FluorChem Imaging System.
The brightness of each well was quantified with FluorChem Imaging System
Software and normalized to enzyme concentration, and the percent enzyme
inhibition was determined. The intensity of light emission was proportional to
the amount of functional enzyme and correlated negatively with the test
compound’s effectiveness as hMGL inhibitor.
Interaction of Inhibitors with hMGL and Preparation of Peptide
Hydrolysates for MALDI-TOF MS
Purified hMGL (3.1 mg, 3 mM) in 10mM Tris-HCl ([pH 8.0], (30 ml) was incubated
for 1 hr at room temperature without or with test compound present at a known
molar ratio to hMGL. After evaluation of hMGL inhibition by AM6701 or NAM
(above), the incubation was terminated by rapid desalting with a Bio-Spin 6
column in 50 mM ammonium bicarbonate buffer containing 0.02% CYMAL
(pH 8.0). The desalted hMGL was digested with trypsin (200 ng) overnight
either directly or after reduction alkylation under mild conditions at room
temperature with dithiothreitol (17 mM for 30 min) and iodoacetamide
(55 mM for 1 hr in the dark; Zvonok et al., 2007).
MALDI-TOF MS Analysis
All MS data were acquired on a 4800 Maldi TOF/TOF mass spectrometer (Ap-
plied Biosystems, Framingham, MA) fitted with a 200 Hz solid-state ultraviolet
laser (wavelength 355 nm) from samples spotted on Opti-TOF 384-well plate
inserts. Each sample of protein digest was crystallized by spotting 0.5 ml tryptic
digest and 0.5 ml a-cyano-4-hydroxycinnamic acid matrix (5 mg/mL in aque-
ous 60% acetonitrile/0.1% trifluoroacetic acid). After crystallization, the driedChemistry & Biology 15, 8spot was washed with 5 ml aqueous 0.1% trifluoroacetic acid for rapid desalt-
ing. In those cases where trace residual salt and detergent suppressed signal,
the digest was diluted 10-fold withmatrix solution, and 1 ml of the diluted digest
was spotted for analysis. Spectra were acquired by accumulating data from
several positions within each sample well to determine the ions present. All
MS spectra were externally calibrated using a mixture of peptide standards
(des-Arg1-bradykinin at MH+ 904.4681; angiotensin I at MH+ 1296.6853;
Glu-fibrino peptide at MH+ 1570.6774; ACTH [clip 1–17] at MH+ 2093.0867;
ACTH [clip 18–39] at MH+ 2465.1989; and ACTH [clip 7–38] at MH+
3657.9294). MS/MS spectra were acquired on selected ions of interest. The
instrument was calibrated in the MS/MS mode using five daughter ions (at
m/z 175.119, 684.346, 813.389, 1056.475, and 1441.634) generated from
the fragmentation of Glu-fibrino peptide (MH+ 1570.6774.) MS/MS spectra
were acquired under the following conditions: precursor isolation resolution
of 200; collision energy of 2 kV; cell pressure of 2 3 105 torr; air as collision
gas. Accumulation was performed until spectra were of optimal quality.
Data analyses were performed by comparing the monoisotopic peaks with
the theoretical molecular weights corresponding to the expected peptide di-
gestion products. Themaximum error allowedwas set to 100 ppm. Theoretical
molecular weights of expected peptides after digestion were calculated using
MS-Digest (University of California, San Francisco, Mass Spectrometry Facil-
ity, San Francisco, CA) and FindPept and FindMod tools (ExPASy server,
Swiss Institute of Bioinformatics, Geneva, Switzerland).
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